Literature DB >> 16264433

Drug therapy for atrial fibrillation: where do we go from here?

Richard L Page1, Dan M Roden.   

Abstract

Atrial fibrillation, the most common cardiac arrhythmia requiring medical attention, has effects that range from mild symptoms to devastating stroke. Although treatments have evolved since the foxglove plant (later identified as containing digitalis) was first administered to slow the heart rate, satisfactory drug therapy has not been developed. In this review we describe present-day medical options and developments of future therapies to treat atrial fibrillation and maintain normal sinus rhythm.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16264433     DOI: 10.1038/nrd1876

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  15 in total

1.  Targeting atrioventricular differences in ion channel properties for terminating acute atrial fibrillation in pigs.

Authors:  Sandeep V Pandit; Sharon Zlochiver; David Filgueiras-Rama; Sergey Mironov; Masatoshi Yamazaki; Steven R Ennis; Sami F Noujaim; Antony J Workman; Omer Berenfeld; Jerome Kalifa; José Jalife
Journal:  Cardiovasc Res       Date:  2010-11-13       Impact factor: 10.787

Review 2.  [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers].

Authors:  U Ravens; E Wettwer; U Schotten; R Wessel; D Dobrev
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

3.  Dronedarone.

Authors:  Richard L Page; Bashar Hamad; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

Review 4.  Mathematical approaches to understanding and imaging atrial fibrillation: significance for mechanisms and management.

Authors:  Natalia A Trayanova
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

Review 5.  Emerging concepts in the pharmacogenomics of arrhythmias: ion channel trafficking.

Authors:  William T Harkcom; Geoffrey W Abbott
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-08

6.  American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association.

Authors:  N A Mark Estes; Ralph L Sacco; Sana M Al-Khatib; Patrick T Ellinor; Judy Bezanson; Alvaro Alonso; Charles Antzelevitch; Randall G Brockman; Peng-Sheng Chen; Sumeet S Chugh; Anne B Curtis; John P DiMarco; Kenneth A Ellenbogen; Andrew E Epstein; Michael D Ezekowitz; Pierre Fayad; Brian F Gage; Alan S Go; Mark A Hlatky; Elaine M Hylek; Michael Jerosch-Herold; Marvin A Konstam; Richard Lee; Douglas L Packer; Sunny S Po; Eric N Prystowsky; Susan Redline; Yves Rosenberg; David R Van Wagoner; Kathryn A Wood; Lixia Yue; Emelia J Benjamin
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

Review 7.  Interdependent Relationship Between Atrial Fibrillation and Sinus Rhythm at the Hypothetical Interface of Atrial Fibrillation, Autonomic Tone, Sinoatrial Node and Inflammation : Analytical Review, Reconsiderations, Speculations and New Insights.

Authors:  Petras Stirbys
Journal:  J Atr Fibrillation       Date:  2012-12-16

8.  Ectopic activity in the rat pulmonary vein can arise from simultaneous activation of alpha1- and beta1-adrenoceptors.

Authors:  V Maupoil; C Bronquard; J-L Freslon; P Cosnay; I Findlay
Journal:  Br J Pharmacol       Date:  2007-02-26       Impact factor: 8.739

9.  The plateau outward current in canine ventricle, sensitive to 4-aminopyridine, is a constitutive contributor to ventricular repolarization.

Authors:  A Sridhar; D N Q da Cunha; V A Lacombe; Q Zhou; J J Fox; R L Hamlin; C A Carnes
Journal:  Br J Pharmacol       Date:  2007-08-13       Impact factor: 8.739

Review 10.  [New developments in the antiarrhythmic therapy of atrial fibrillation].

Authors:  Ursula Ravens
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2014-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.